Norepinephrine
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


Norepinephrine
Description:
Norepinephrine (Levarterenol; L-Noradrenaline) is a potent adrenergic receptor (AR) agonist. Norepinephrine activates α1, α2, β1 receptors[1][2][3][4].Product Name Alternative:
Levarterenol; L-NoradrenalineUNSPSC:
12352005Hazard Statement:
H300, H310, H330Target:
Adrenergic Receptor; Autophagy; Endogenous MetaboliteType:
Natural ProductsRelated Pathways:
Autophagy; GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal SignalingField of Research:
Endocrinology; Cardiovascular Disease; CancerAssay Protocol:
https://www.medchemexpress.com/Norepinephrine.htmlPurity:
99.61Solubility:
0.5 M HCl : ≥ 25 mg/mL|DMSO : 50 mg/mL (ultrasonic; adjust pH to 2 with HCl)Smiles:
OC1=CC=C([C@@H](O)CN)C=C1OMolecular Formula:
C8H11NO3Molecular Weight:
169.18Precautions:
H300, H310, H330References & Citations:
[1]MacGregor DA, et al. Relative efficacy and potency of beta-adrenoceptor agonists for generating cAMP in human lymphocytes. Chest. 1996 Jan;109 (1) :194-200.|[2]Littlejohn NK, et al. Suppression of Resting Metabolism by the Angiotensin AT2 Receptor. Cell Rep. 2016 Aug 9;16 (6) :1548-60.|[3]Brian P Ramos, et al. Adrenergic pharmacology and cognition: focus on the prefrontal cortex. Pharmacol Ther. 2007 Mar;113 (3) :523-36.|[4]Xinyu Xu, et al. Binding pathway determines norepinephrine selectivity for the human β 1 AR over β 2 AR. Cell Res. 2021 May;31 (5) :569-579.|[5]Xiao D, et al. "Inhibition of DNA methylation reverses norepinephrine-induced cardiac hypertrophy in rats." Cardiovascular research 101.3 (2014) : 373-382.|[6]Yamazaki, et al. "Norepinephrine induces the raf-1 kinase/mitogen-activated protein kinase cascade through both α1-and β-adrenoceptors." Circulation 95.5 (1997) : 1260-1268.Shipping Conditions:
Room TemperatureStorage Conditions:
4°C (Powder, protect from light, stored under nitrogen)Scientific Category:
Natural ProductsClinical Information:
LaunchedIsoform:
Human Endogenous Metabolite; Microbial Metabolite; α adrenergic receptor; β adrenergic receptorCitation 01:
ACS Nano. 2022 Aug 23;16 (8) :12553-12568.|Anal Chem. 2025 Jul 15;97 (27) :14220-14229.|Basic Res Cardiol. 2025 Apr;120 (2) :423-441.|Biochem Biophys Res Commun. 2023 May 21:657:108-118.|bioRxiv. 2023 Oct 13.|bioRxiv. 2024 July 31.|bioRxiv. 2024 November 03.|Cell Commun Signal. 2024 Jul 25;22 (1) :375.|Cell Death Dis. 2020 Aug 18;11 (8) :644.|Cell Discov. 2025 May 13;11 (1) :46.|Cell Mol Immunol. 2023 Feb;20 (2) :175-188.|Cell Rep Med. 2023 Jun 20;4 (6) :101061.|Cell Stem Cell. 2025 May 1;32 (5) :778-794.e10.|Eur J Pharmacol. 2022 Jul 15:927:175022.|Food Science and Human Wellness. 2023 Nov;12 (6) ;2061-2072.|Gene. 2023 Dec 20:888:147753.|Int J Mol Sci. 2022 Oct 17;23 (20) :12420.|Int J Mol Sci. 2025 Mar 2;26 (5) :2243.|J Am Heart Assoc. 2019 Jan 8;8 (1) :e009871.|J Biol Chem. 2024 Oct 23:107924.|J Cancer. 2024 Sep 9;15 (17) :5691-5709.|J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Aug 15:1092:220-227.|J Ethnopharmacol. 2025 Jan 30;337 (Pt 2) :118860.|J Physiol. 2025 Oct 9.|J Therm Biol. 2024 Jul 2:123:103906.|Mater Today Bio. 2025 Oct 2:35:102364.|Mol Cell Endocrinol. 2024 Nov 16:112417.|Nat Commun. 2022 Jul 25;13 (1) :4278.|Nat Commun. 2024 May 7;15 (1) :3834.|Neurochem Int. 2021 Feb:143:104942.|Ocul Immunol Inflamm. 2024 Dec 27:1-15.|Sci Rep. 2022 Jun 15;12 (1) :9936.|SSRN. 2023 May 8.|Transl Psychiatry. 2025 May 17;15 (1) :172.|Turk J Med Sci. 2025 Feb 19;55 (2) :509-517. |Adv Sci (Weinh) . 2025 Oct 6:e04817.|Br J Pharmacol. 2020 Aug;177 (15) :3389-3402. |Cell Rep. 2019 Dec 3;29 (10) :2936-2943.e4. |Cell. 2025 Sep 18;188 (19) :5142-5156.e23.|J Nutr Biochem. 2018 Aug:58:110-118.|Leiden University. Institute of Biology Leiden (IBL), Faculty of Science.|Nature. 2025 Jul;643 (8070) :192-200.|Neuroscience. 2019 Mar 1:401:59-72.|Redox Rep. 2025 Dec;30 (1) :2494314.|Research Square Preprint. 2021 Aug.|Theranostics. 2022 Jun 6;12 (10) :4718-4733.|bioRxiv. 2025 Oct 2.|Cardiovasc Res. 2018 Feb 1;114 (2) :300-311. |Cell Biochem Funct. 2024 Jan;42 (1) :e3915.|FASEB J. 2020 Nov;34 (11) :14892-14904.|Invest Ophthalmol Vis Sci. 2025 Jun 2;66 (6) :13.|Nat Commun. 2025 Jun 5;16 (1) :5215.CAS Number:
[51-41-2]
